These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 27268638

  • 21. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
    Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI.
    Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X.
    Cancer; 2014 Dec 15; 120(24):3952-7. PubMed ID: 25116271
    [Abstract] [Full Text] [Related]

  • 25. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
    Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, Birtwistle J, Plant T, Afzal Z, Jefferis R, Drayson MT.
    J Immunol Methods; 2013 May 31; 391(1-2):1-13. PubMed ID: 23388695
    [Abstract] [Full Text] [Related]

  • 26. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, Galanis Z, Kalpadakis C, Dimou M, Kyriakou E, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Panayiotidis P, Pangalis GA.
    Br J Haematol; 2007 May 31; 137(3):240-3. PubMed ID: 17408464
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
    Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM.
    Hematol Oncol; 2012 Sep 31; 30(3):156-62. PubMed ID: 22028144
    [Abstract] [Full Text] [Related]

  • 29. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B, Rouger E, Rousseau C, Escoffre M, Sébillot M, Bendavid C, Minvielle S, Avet-Loiseau H, Decaux O, Moreau C.
    Clin Chem Lab Med; 2019 Aug 27; 57(9):1397-1405. PubMed ID: 30973821
    [Abstract] [Full Text] [Related]

  • 30. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E, Miravalles E, Bergón E, Miranda I, Bergón M.
    Clin Chem Lab Med; 2005 Aug 27; 43(1):32-7. PubMed ID: 15653439
    [Abstract] [Full Text] [Related]

  • 31. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma.
    Meddour Y, Rahali MC, Belakehal SE, Ardjoun FZ, Chaib S, Djidjik R.
    Clin Lab; 2018 Apr 01; 64(4):551-558. PubMed ID: 29739080
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma].
    Chen HF, Hou J, Yuan ZG, Wang DX, Fu WJ, Chen YB.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb 01; 29(2):113-6. PubMed ID: 18681313
    [Abstract] [Full Text] [Related]

  • 34. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
    Zhao L, Tian Z, Fang Q.
    Zhonghua Nei Ke Za Zhi; 2016 Mar 01; 55(3):186-90. PubMed ID: 26926369
    [Abstract] [Full Text] [Related]

  • 35. Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients.
    Bourguignon C, Chenine L, Bargnoux AS, Leray-Moragues H, Canaud B, Cristol JP, Morena M.
    J Nephrol; 2016 Apr 01; 29(2):251-257. PubMed ID: 26022721
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory.
    Caponi L, Romiti N, Koni E, Fiore AD, Paolicchi A, Franzini M.
    Crit Rev Clin Lab Sci; 2020 Mar 01; 57(2):73-85. PubMed ID: 31612753
    [Abstract] [Full Text] [Related]

  • 38. Assessment of serum free light chain levels in healthy adults immediately after marathon running.
    Campbell JP, Eijsvogels TM, Wang Y, Hopman MT, Jacobs JF.
    Clin Chem Lab Med; 2016 Mar 01; 54(3):459-65. PubMed ID: 26351935
    [Abstract] [Full Text] [Related]

  • 39. Automated alarm to detect antigen excess in serum free immunoglobulin light chain kappa and lambda assays.
    Urdal P, Amundsen EK, Toska K, Klingenberg O.
    Scand J Clin Lab Invest; 2014 Oct 01; 74(7):575-81. PubMed ID: 25007050
    [Abstract] [Full Text] [Related]

  • 40. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
    Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R.
    Clin Lymphoma Myeloma Leuk; 2010 Feb 01; 10(1):E10-3. PubMed ID: 20223721
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.